Singapore-based ASLAN Pharmaceuticals has signed an understanding with the National Cancer Centre of Singapore (NCCS) to study novel combination therapies to treat gastric cancer, hepatocellular carcinoma and cholangiocarcinoma, in its second move in this month to explore wider avenues for its existing clinical trial candidates.
Hays Recruiting in Singapore says jobs in biopharma niches in manufacturing, regulatory and sales are up for grabs in the island nation, topping its latest quarterly regional outlook of skills in demand through September 2015, according to a press release.
Singapore, a nation working to raise its profile in the biopharma world, has kicked off the first-ever clinical trial of a locally invented drug, working with Duke University on a novel cancer treatment it hopes will spur more R&D.
Several years ago, GlaxoSmithKline committed $50 million to set up an antibiotics facility in Singapore to do continuous processing, a radically different manufacturing approach that has a much smaller footprint, and so much lower operating costs and less environmental impact, than traditional batch processing. The drugmaker now says it is ready to embark on a £38 million expansion there.
Singapore's state investment company just led an ongoing $40 million financing round supporting Hello, maker of the Sense sleep monitor, demonstrating growing interest in health and fitness-related gadgets among investors, if not the general public.
A Singapore-led clinical group has published a study of a novel approach to investigating how genes affect options to treat liver cancer, highlighting the city-state's growing role in oncology research.
Singapore's research agency and Duke-National University of Singapore have signed an agreement to collaborate with U.S. biotech Visterra on getting a promising treatment against dengue fever to the clinical-trial stage.
Singapore, like other Asian countries looking to woo pharmaceutical manufacturers, is moving quickly to meet increasing demand for high-quality water required by strict regulations in the U.S. and European Union.
In a deal spanning three continents, Asia's Strides Arcolab is paying nearly $300 million for the Australian generics business of Africa's Aspen Pharmacare Holdings. The deal also includes some branded drugs.
Indonesia's Kalbe Farma is making this year an expansion year as it moves beyond its shores and into Singapore and Thailand and their over-the-counter drug markets as a regional trade pact looks set to start at the end of the year. It also has corporate eyes set on even more countries, with a focus on West Africa.